Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolina Llanos

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Pharmaceutical Research|March 2, 2022
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD PatientsCarolina Llanos-Paez, Claire Ambery, Shuying Yang, et al.
Arthritis and Rheumatism|February 5, 2010
Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart blockPeter M Izmirly, Carolina Llanos, Lela A Lee, et al.
Revista Medica De Chile|November 29, 2005
[The influence of -238 and -308 TNF alpha polymorphisms on the pathogenesis and response to treatment in rheumatoid arthritis]Carolina Llanos, Lilian Soto, Francisca Sabugo, et al.
The American Journal of Cardiology|April 14, 2009
Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) StudyDeborah M Friedman, Mimi Y Kim, Joshua A Copel, et al.
Current Gene Therapy|October 26, 2011
Genetic and pharmacological modulation of dendritic cell-T cell interactions as a therapeutic strategy for systemic lupus erythematosusCarolina Llanos, Leandro J Carreño, Miguel A Gutierrez, et al.
Frontiers in Immunology|May 1, 2019
Innate Immune Cells' Contribution to Systemic Lupus ErythematosusAndrés A Herrada, Noelia Escobedo, Mirentxu Iruretagoyena, et al.
The AAPS Journal|June 3, 2021
Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled TrialCarolina Llanos-Paez, Claire Ambery, Shuying Yang, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 19, 2025
A Combined Model-Based Meta-Analysis of Aggregated and Individual FEV1 Data From Randomized COPD TrialsLiang Yang, Carolina Llanos-Paez, Shuying Yang, et al.
Immunology|August 2, 2017
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotypeJaviera Obreque, Fabián Vega, Andy Torres, et al.
The Journal of Rheumatology|November 3, 2005
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritisJohn C Mavropoulos, Miguel Cuchacovich, Carolina Llanos, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Pharmaceutical Research|March 2, 2022
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD PatientsCarolina Llanos-Paez, Claire Ambery, Shuying Yang, et al.
Arthritis and Rheumatism|February 5, 2010
Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart blockPeter M Izmirly, Carolina Llanos, Lela A Lee, et al.
Revista Medica De Chile|November 29, 2005
[The influence of -238 and -308 TNF alpha polymorphisms on the pathogenesis and response to treatment in rheumatoid arthritis]Carolina Llanos, Lilian Soto, Francisca Sabugo, et al.
The American Journal of Cardiology|April 14, 2009
Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) StudyDeborah M Friedman, Mimi Y Kim, Joshua A Copel, et al.
Current Gene Therapy|October 26, 2011
Genetic and pharmacological modulation of dendritic cell-T cell interactions as a therapeutic strategy for systemic lupus erythematosusCarolina Llanos, Leandro J Carreño, Miguel A Gutierrez, et al.
Frontiers in Immunology|May 1, 2019
Innate Immune Cells' Contribution to Systemic Lupus ErythematosusAndrés A Herrada, Noelia Escobedo, Mirentxu Iruretagoyena, et al.
The AAPS Journal|June 3, 2021
Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled TrialCarolina Llanos-Paez, Claire Ambery, Shuying Yang, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 19, 2025
A Combined Model-Based Meta-Analysis of Aggregated and Individual FEV1 Data From Randomized COPD TrialsLiang Yang, Carolina Llanos-Paez, Shuying Yang, et al.
Immunology|August 2, 2017
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotypeJaviera Obreque, Fabián Vega, Andy Torres, et al.
The Journal of Rheumatology|November 3, 2005
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritisJohn C Mavropoulos, Miguel Cuchacovich, Carolina Llanos, et al.
Pageof 5